Your browser is no longer supported. Please, upgrade your browser.
NVUS Novus Therapeutics, Inc. monthly Stock Chart
NVUS [NASD]
Novus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own0.50% Shs Outstand9.61M Perf Week-6.37%
Market Cap46.61M Forward P/E- EPS next Y-1.37 Insider Trans254.22% Shs Float7.27M Perf Month0.00%
Income-11.10M PEG- EPS next Q-0.40 Inst Own52.80% Short Float1.09% Perf Quarter-23.02%
Sales- P/S- EPS this Y81.40% Inst Trans-12.59% Short Ratio0.67 Perf Half Y-13.05%
Book/sh2.29 P/B2.12 EPS next Y-3.20% ROA-47.70% Target Price8.25 Perf Year0.00%
Cash/sh- P/C- EPS next 5Y- ROE-51.60% 52W Range3.12 - 8.61 Perf YTD19.46%
Dividend- P/FCF- EPS past 5Y6.80% ROI- 52W High-44.60% Beta0.31
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low52.88% ATR0.45
Employees8 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)42.86 Volatility6.49% 10.09%
OptionableNo Debt/Eq0.00 EPS Q/Q78.90% Profit Margin- Rel Volume0.27 Prev Close4.85
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume118.11K Price4.77
Recom2.00 SMA200.10% SMA50-14.92% SMA200-6.27% Volume3,729 Change-1.65%
Feb-13-18Initiated Ascendiant Capital Markets Buy $7
Sep-07-18 09:25AM  Novus Therapeutics to Postpone Offering of Common Stock Business Wire +19.42%
Sep-04-18 04:05PM  Novus Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Aug-07-18 08:30AM  Novus Therapeutics Reports Second Quarter 2018 Financial Results Business Wire
Jun-19-18 07:30AM  Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media Business Wire +8.00%
May-11-18 09:15AM  Novus Therapeutics Reports First Quarter 2018 Financial Results Business Wire +11.98%
Apr-02-18 09:00AM  Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Business Wire -5.95%
Jan-05-18 07:20PM  Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)? Simply Wall St.
Nov-21-17 03:00PM  Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
12:49PM  Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)? Simply Wall St.
Nov-08-17 04:52PM  Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 04:01PM  Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President PR Newswire -6.56%
Oct-05-17 09:26AM  Whats The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)? Simply Wall St.
Aug-09-17 06:08PM  Novus Therapeutics Reports Second Quarter 2017 Results PR Newswire
Jul-10-17 06:30AM  Novus Therapeutics Announces Change in Management PR Newswire
Jun-12-17 08:00AM  Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TURKEL CATHERINE C.PresidentSep 12Buy5.0216,63283,47678,199Sep 13 08:00 PM
TURKEL CATHERINE C.PresidentSep 11Buy4.5617,04877,67161,567Sep 13 08:00 PM
TURKEL CATHERINE C.PresidentSep 05Buy3.978053,193805Sep 07 08:00 PM